|
|
|
|
|
|
|
|
|
|
|
|
|
08.12.25 - 22:33
|
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida....
|
|
|
|
|
|
|
|
|
|
|
|
|
08.08.25 - 22:06
|
Exicure, Inc. Reports Second Quarter 2025 Financial Results (Business Wire)
|
|
|
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended June 30, 2025.
Second Quarter 2025 Financial Results
Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024.
Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended June 30, 2025, as compared to $0 for the quarter ended June 30, 2024. The increase in R&D expense of $0.9 million for the three months ended June 30, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. (“GPCR USA”), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses.
General and Administrative (G&A) Expense: General and administrative expenses were $1.5 million for the quarter ended June 30, 2...
|
|
|
|
|
|
|
02.07.25 - 15:33
|
XFRA: Diverse ISINs: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ALTURA ENERGY CORP. Y020 CA02210E1016
BECKETTS INC. O.N. T270 CA07568L1022
CAMINO MINERALS XC0 CA1380503070
GLENSTAR MINERALS INC. VO20 CA37888C1023
GOLD FINDERS RESOURCES 6NR CA38059A1075
NOBLE PLAINS URANIUM INE0 CA65510H1082
PARADIGM GOLD CORP. C5N CA69902F1009
SOKOMAN MIN.CORP. NEW 3PJ CA83410N1096
AMS-OSRAM UNSPON.ADR NEW DQW0 US03217C2052
DBV TECH.SP.ADR 5 EO-10 DBV1 US23306J3095
EMBRACER GROUP UNSP.ADR/1 TH93 US29082P2039
EXICURE INC. DL-,0001 2H0 US30205M3097
FITLIFE BRANDS INC. O.N. QO...
|
|
|
|
|
27.06.25 - 22:06
|
Exicure, Inc. Reports First Quarter 2025 Financial Results (Business Wire)
|
|
|
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025.
First Quarter 2025 Financial Results
Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024.
Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. (“GPCR USA”), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses.
General and Administrative (G&A) Expense: General and administrative expenses were $2.2 million for the quarter ended March...
|
|
|
|
|
28.05.25 - 23:03
|
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q (Business Wire)
|
|
|
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2025 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).
Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until November 17, 2025, to regain compliance.
The Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as...
|
|
|
18.03.25 - 21:06
|
Exicure, Inc. Reports Full Year 2024 Financial Results (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.
2024 Financial Results
Cash Position: Cash and cash equivalents were $12.5 million as of December 31, 2024, as compared to $0.8 million as of December 31, 2023. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be needed to fund our ongoing operations and exploratio...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
